Alvogen and Dr Reddy’s US Suboxone Rivals Face Off Against Sandoz’ Authorized Generic
Executive Summary
Alvogen and Dr Reddy’s have launched generic versions of Indivior’s Suboxone in the US, after the Supreme Court denied the originator’s attempt to further frustrate generic launches. But these two versions will compete with an authorized generic launched by Indivior through Sandoz.
You may also be interested in...
Sun Pharma Faces Nine-Year Wait After US Zubsolv Ruling
Another ANDA sponsor has tried and failed to navigate Orexo’s patents for its opioid dependence sublingual tablets, Zubsolv.
Dr Reddy’s Gets $72m Payout From Suboxone Settlement
Dr Reddy’s is in line for a $72m payout after settling US patent and antitrust litigation over Suboxone with Indivior.
Two Firms Fight FDA Exclusivity Battles In US
Alvogen contends Teva forfeited 180-day exclusivity with its settlement, while Sandoz claims Sanofi’s MS drug Aubagio isn’t an NCE because it is an active metabolite.